1 / 6

Hereditary Angioedema (HAE) Therapeutics Development Pipelin

This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) and special features on late-stage and discontinued projects.

RamonEMarshall01
Télécharger la présentation

Hereditary Angioedema (HAE) Therapeutics Development Pipelin

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 29-May-2015 No. of pages: 78 Single User License: US $2000 Browse more Reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 This report gives far reaching data on the helpful advancement for Hereditary Angioedema (HAE), complete with relative examination at different stages, therapeutics appraisal by medication target, component of activity (MoA), course of organization (RoA) and particle sort, alongside most recent upgrades, and included news and press discharges. It additionally surveys key players included in the restorative improvement for Hereditary Angioedema (HAE) and extraordinary components on late-stage and ended activities. The report improves choice making capacities and help to make powerful counter techniques to increase upper hand. It reinforces R&D pipelines by recognizing new targets and MOAs to create first-in-class and best-in-class items. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 Companies Discussed/Mentioned in this Research : BioCryst Pharmaceuticals, Inc., Cevec Pharmaceuticals GmbH, CSL Limited, Dyax Corp., Global Blood Therapeutics, Inc., iBio, Inc., Isis Pharmaceuticals, Inc., Pharming Group N.V., Ra Pharmaceuticals, Inc. and Shire Plc Drugs Profile Discussed in this Research : BCX-4161, BCX-7353, BEL-0215, C1 esterase inhibitor (human), C1 esterase inhibitor (human), C1 esterase inhibitor (recombinant), C1 esterase inhibitor (recombinant), CSL-312, DX-2930, icatibant acetate, ISIS-PKKRx, Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema, Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema, Small Molecule for Hereditary Angioedema and Synthetic Peptide to Inhibit Kallikrein for Hereditary Angioedema. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 Scope For Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 • The report provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Hereditary Angioedema (HAE) and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE) • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Hereditary Angioedema (HAE) - Pipeline Review, H1 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related